Published in final edited form as:

ACS Infect Dis. 2015 May 8; 1(5): 215–221. doi:10.1021/acsinfecdis.5b00026.

Oxa, Thia, Heterocycle, and Carborane Analogues of SQ109: Bacterial and Protozoal Cell Growth Inhibitors

Kai Li[1,&], **Yang Wang**[1,&], **Gyongseon Yang**[2], **Sooyoung Byun**[2], **Guodong Rao**[1], **Carolyn Shoen**[3], **Hongliang Yang**[4], **Anmol Gulati**[1], **Dean C. Crick**[4], **Michael Cynamon**[3], **Guozhong Huang**[5], **Roberto Docampo**[5], **Joo Hwan No**[2], and **Eric Oldfield**[1,*]

[1]Department of Chemistry, University of Illinois at Urbana-Champaign, 600 South Mathews Avenue, Urbana, IL 61801

[2]Leishmania Research Laboratory, Institut Pasteur Korea, Seongnam-si, Gyeonggi-do, Republic of Korea, 463-400

[3]Veterans Affairs Medical Center, 800 Irving Avenue, Syracuse, NY 13210

[4]CVMBS Microbiology, Immunology and Pathology Department, Colorado State University, 1682 Campus Delivery, Fort Collins, CO 80523-1601

[5]Center for Tropical and Emerging Global Diseases and Department of Cellular Biology, University of Georgia, Athens, GA 30602

Abstract

We synthesized a library of 48 analogs of the *Mycobacterium tuberculosis* cell growth inhibitor SQ109 in which the ethylene diamine linker was replaced by oxa-, thia- or heterocyclic species, and in some cases, the adamantyl group was replaced by a 1,2-carborane or the N-geranyl group by another hydrophobic species. Compounds were tested against *Mycobacterium tuberculosis* (H37Rv and/or Erdman), *Mycobacterium smegmatis*, *Bacillus subtilis*, *Escherichia coli*, *Saccharomyces cerevisiae*, *Trypanosoma brucei* and two human cell lines (human embryonic kidney, HEK293T, and the hepatocellular carcinoma, HepG2). Most potent activity was found against *T. brucei*, the causative agent of human African trypanosomiasis, and involved targeting of the mitochondrial membrane potential with 15 SQ109 analogs being more active than was SQ109 in cell growth inhibition, having IC_{50} values as low as 12 nM (5.5 ng/mL) and a selectivity index of ~300.

*Corresponding Author: eoldfiel@illinois.edu. Tel: 217-333-3374.
&These authors contributed equally.

Author Contributions

K.L. Y.W. and E.O. designed research; K.L. Y.W. and A.G. synthesized compounds; Y.W. G.Y. S.-Y.B. G.R. C.S. D.C. M.C. and J.-H.N. performed cell growth inhibition experiments; G.H. and R.D. performed mitochondrial membrane potential experiment; Y.W. and E.O. analyzed data. Y.W. and E.O. wrote the paper.

The authors declare no competing financial interest.

Supporting Information

Full details of all assays; representative dose-response curves; selectivity index results; mitochondrial membrane bioenergetics; full synthesis and characterization of SQ-109 and its analogs as well as qNMR spectra. This material is available free of charge via the Internet at http://pubs.acs.org.

Keywords

Tuberculosis; sleeping-sickness; uncouplers; menaquinone; trypanosomes

The occurrence of drug resistance is a growing problem[1,2]. One serious threat is with tuberculosis since there are many millions of individuals infected with *Mycobacterium tuberculosis*, the causative agent of tuberculosis, resulting in ~1.5 million deaths per year[3]. Chemotherapy is lengthy and there is increasing resistance to antibiotics. New drugs and drug leads are thus needed. One of the oldest drugs for tuberculosis treatment is ethambutol (**1**), an ethylenediamine derivative, and in recent work some 74,000 analogs[4,5] of ethambutol including the ethylenediamine SQ109[4] (**2**) and the piperidine SQ609[5] have shown promise. One mechanism of action of SQ109 has been proposed to be inhibition of the membrane protein MmpL3[6], a trehalose monomycolate transporter[7]. There have been no reports of spontaneous resistance to SQ109 but resistance to somewhat similar species involving MmpL3 has been reported[8,9], and these *mmpL3* mutants have modest cross-resistance to SQ109[6]. SQ109 also has activity against other bacteria (e.g. *Helicobacter pylori*[10]), fungi (e.g. *Candida abicans*[11]) as well as the malaria parasite *Plasmodium falciparum*, all of which lack the *mmpL3* gene, so in these organisms there must be other targets/mechanisms of action. SQ109 analogs might thus be of interest as anti-infective leads against a range of organisms. Here, we elected to synthesize four types of SQ109-inspired species that might have activity against bacteria, fungi or protozoa.

We synthesized the SQ109 analogs (**3-50**) shown in Figures 1–3: a) 13 alkanolamine analogs (**3-15**, Figure 1); b) 3 thia analogs (**16-18**, Figure 1); c) 23 heterocycle-containing analogs (**19-41**, Figure 2) and d) 9 carborane-containing analogs (**42-50**, Figure 3). Full synthesis and characterization details are given in the Supporting Information.

In previous work, we found that compound **51** (Figure 1), the alkanolamine analog of SQ109, was more active (0.035 μg/mL) against *M. tuberculosis*) than was SQ109 (0.15 μg/mL)[12]. We therefore first synthesized and tested 13 alkanolamine-analogs of SQ109 (**3-15**, Figure 1) against *M. tuberculosis*, *M. smegmatis*, *B. subtilis*, *S. cerevisiae*, *E. coli*, *T. brucei*, HEK293T and HepG2 cells. MIC (*Mycobacterium tuberculosis* H37Rv, *Mycobacterium tuberculosis* Erdman), IC_{50} (*M. smegmatis*, *B. subtilis*, *E. coli*, *S. cerevisiae*, *T. brucei*) and CC_{50} (HEK293T and HepG2) values are given in Table 1 with the *M. tuberculosis* and *T. brucei* results shown, for convenience, below the structures in Figure 1.

There were several compounds with promising activity against *M. tuberculosis*. The most active compound was **5**, an analog of SQ109 (**2**) in which the ethylenediamine nitrogen attached to the adamantane group was replaced by an oxygen, and the geranyl (C_{10}) side-chain by a farnesyl (C_{15}) group. The MIC was 0.39 μg/mL for *M. tuberculosis* H37Rv and 1.0 μg/mL for *M. tuberculosis* Erdman (MtE), Figure 1 and Table 1, to be compared with 0.1–0.5 μg/mL for SQ109 (**2**), in both strains and 0.035 μg/mL for **51** in *M. tuberculosis* H37Rv[12]. The reduced side-chain species **6** was ~10–20x less active than was the farnesyl analog. The isopentenyl ethanolamine analog (**3**) was also less active than was **5**, and reduction (**4**) reduced activity further. Incorporation of a 1-Me or 1 *i*-Pr group (**8**, **9**)

decreased activity when compared with **51**. The presence of a 1-OH group (**7**) also resulted in decreased activity (0.78 μg/mL) over that found with SQ109. The O-methylated analogs (**10**, **11**) showed worse activity against MtE compared with the 1-OH species. Replacement of the isoprenoid side-chains with aromatic groups (**12-15**) blocked all activity and in other work[12] we found the diether analog of **2** was also inactive[12]. These results indicate that optimum activity is found with a single nitrogen and that the order of activity of these alkanolamines is geranyl≫farnesyl≫isopentenyl, and that the reduced side-chain containing species are all less active than the unsaturated species. In the other assays (*B. subtilis*, *E. coli* and *S. cerevisiae*) the most potent cell growth inhibitor (Table 1) was **5**, the N-farnesyl ethanolamine.

With the trypanosomatid parasite *T. brucei*, we found that SQ109 itself had quite potent activity against bloodstream form (BSF) parasites with an IC_{50} of 0.078 μg/mL and a selectivity index (SI), defined as SI = CC_{50} (HEK293T)/IC_{50} (*T. brucei*) or CC_{50} (HepG2)/IC_{50} (*T. brucei*) in the 15–24 range, Table 1. The most active SQ109 analogs were **10** (IC_{50} = 0.23 μg/mL), **8** (IC_{50} = 0.33 μg/mL) and **6** (IC_{50} = 0.50 μg/mL) with selectivity indices of 23, 21 (**10**), 19, 16 (**8**) and ~3–4 (**6**), so these analogs are less promising than is SQ109 against *T. brucei*. We also tested the SQ109 analog reported previously (**51**) to have potent activity against *M. tuberculosis*, but again it was slightly less active and had a worse SI as compared to SQ109 (Table 1).

We next investigated the 3 thia-analogs of SQ109 (**16-18**) in which the N attached to adamantane in SQ109 (O in the more active ethanolamine analog) was replaced by an S or SO_2 group (providing different H-bonding possibilities), and in two cases the geranyl group was reduced to the per-hydro species. Cell growth inhibition results are shown in Table 1.

As can be seen in Figure 1 and Table 1, the thio-ether **16** had potent activity against *M. tuberculosis* H37Rv with an MIC of 0.39 μg/mL. **16** is the closest analog to SQ109 in the compounds studied here and also had activity against *M. smegmatis* (1.2 μg/mL), *S. cerevisiae* (0.38 μg/mL) and *E. coli* (1.4 μg/mL). Interestingly, in these organisms, the reduced species was even more active (Table 1). The sulfone had weak activity in all assays. The results in *M. tuberculosis* are consistent with the results found for the alkanolamines **5, 6** in that best activity is observed with the unsaturated side-chain containing species. With *T. brucei*, the most active thia-analog was **16** (IC_{50} = 0.31 μg/mL; SI 5–9), followed by **17** (IC_{50} = 0.69 μg/mL; SI 6–7) and **18** (IC_{50} = 0.89 μg/mL, SI = 4–5).

The results described above are of interest in that we show, for the first time, that SQ109 has activity against the parasitic protozoan *T. brucei*, but unlike the situation found with the alkanolamine analogs of SQ109 reported previously[12], none of the new analogs showed improved activity (over that seen with **51)** against *M. tuberculosis*, although **5**, **16** and **17** were all more active than was SQ109 against the Gram negative bacterium, *E. coli* (**5**, IC_{50} = 0.60 μg/mL; **16**, IC_{50} = 1.4 μg/mL; **17**, IC_{50} = 0.70 μg/mL, *versus* IC_{50} = 2.8 μg/mL for SQ109; Table 1), although the computed selectivity indices (using HEK293T and HepG2) are poor (~5).

In previous work[12] we also found that another SQ109 analog, a choline-derivative containing a quaternary ammonium instead of a protonable N, had the most potent activity against a different parasitic protozoan, the malaria parasite *P. falciparum*, in addition to being a very potent inhibitor of respiration, in *M. smegmatis*[12]. We thus reasoned that other cationic analogs of SQ109 might have better anti-bacterial and/or anti-protozoal activity, so we made and tested two further sets of analogs. We first synthesized a series of 23 SQ109 analogs with primarily protonatable (or fixed charge) heterocycle linker groups replacing the ethylenediamine fragment. The heterocycles investigated were neutral (the 1,2,3-triazoles **19, 20**); protonatable (guanidines and amidines, **21**, **40, 41;** and an imidazole, **38**), or they contained a fixed positive charge (imidazoliums and pyridiniums, **23**-**39**). The two neutral triazoles had low activity against *M. tuberculosis* (**19**, MIC = 12, 25 μg/mL; **20**, MIC = 6.2 μg/mL) and *M. smegmatis* (IC_{50} ~5 μg/mL) and essentially no activity against the other bacteria or the fungus.

Of the other heterocyclic compounds investigated, most had some activity against *M. tuberculosis* Erdman (and *M. tuberculosis* H37Rv), Figure 2 and Table 1. However, there were only 3 compounds (**21**, **23, 24**) in which at least one of the *M. tuberculosis* MIC values was <2 μg/mL. Both **21** and **23** contain as a common structural feature the O-CH_2-CH_2-N group found in the potent alkanolamines and in both cases, the nitrogen is expected to have either a formal +1 charge (**23**) or a large positive charge density (**21**, due to the strong basicity of the ligand and charge delocalization), so both resemble the protonated ethanolamines. In **24,** the aliphatic "linker" group is absent, but we now see that this potent inhibitor resembles SQ109 in another way in that it contains the N-C-C-N group found in the ethylenediamine fragment which, in SQ109 is expected to carry a +1 charge (at pH~7), again delocalized most likely over both nitrogens. As can be seen in Table 1, many of the other heterocyclic analogs have activity against the other bacteria as well as the fungus *S. cerevisiae*, but they also inhibited the growth of the two human cell lines (Table 1), resulting in poor selectivity indices.

The results obtained against *T. brucei* were, however, much more encouraging, Table 1. Specifically, we found that there were 15 analogs of SQ109 that had better IC_{50} and SI values than did SQ109 (IC_{50} = 0.078 μg/mL; SI ~15–24, Table 1). A typical set of dose-response curves for the top five *T. brucei* cell growth inhibitors, together with their corresponding effects on HEK293T and HepG2 cell growth, are shown in Figure S1, and selectivity index *versus T. brucei* cell growth inhibition results (for both human cell lines) are shown in Figure S2. The best *T. brucei* IC_{50} value was 5.5 ng/mL, with corresponding SI values of 290 and 370 (Table 1). Clearly, these results are encouraging and as noted above, are reminiscent of the activity of the choline analog of SQ109 against *P. falciparum* in the intra-erythrocytic assay where an IC_{50} = 80 nM (35 ng/mL) was found (corresponding to a SI~400)[12], plus, activity against the two human cell lines is similar to that seen with SQ109 (which is already in advanced clinical trials for tuberculosis).

Next, we sought to see whether improved activity might be found by replacing the adamantyl group by a 1-*o*-carboranyl group, which is similar to the adamantyl group in terms of size, shape and hydrophobicity[13]. We produced the 9 carboranes (**42**-**50**) shown in Figure 3. None had potent activity against *M. tuberculosis* Erdman, Table 1. However, in

almost all cases there was activity against *M. smegmatis*, *B. subtilis*, *S. cerevisiae* and more surprisingly against *E. coli*, with the ~2 μg/mL IC_{50} values found for **42**, **45** against *E. coli* being of interest since we found worse activity against this Gram negative with the other analogs. Reasons for the enhanced activity against *E. coli* are unknown. Three compounds (**45**, **47, 48**) also had IC_{50} < 0.5 μg/mL against *T. brucei*, although none approached the activity (and hence, SI values) seen with the adamantane-containing analogs.

The most potent compound against *M. tuberculosis* Erdman is thus **24** with an MIC of 0.50 μg/mL, and **24** also has a 0.78 μg/mL MIC against *M. tuberculosis* H37Rv (Table 1). What is of interest about **24** is that it closely resembles the structure of SQ109 in that there are adamantyl and geranyl groups and a N-C-C-N linker but here, the linker is an imidazolium, not an ethylenediamine group. The heterocycles (**19**-**41**) as a class have most potent activity against the trypanosomatid parasite *T. brucei* and are also most active against the 2 human cell lines. However, when selectivity index values are calculated it can be seen that **27, 28** have the best IC_{50} values of ~5–7 ng/mL and SI~300. All of the compounds with the best SI (**22**-**37**) also have fixed charge centers, raising the question as to their possible mechanism of action.

In earlier work we found that SQ109 acted as an uncoupler in *E. coli* as well as in *M. smegmatis* and we proposed that this uncoupling activity was important for its activity against *M. tuberculosis*[12]. Similar results have now been reported for a broader range of compounds which are now proposed to act as uncouplers, in *M. tuberculosis*[14], targeting ΔpH, Δψ, or both. We therefore tested SQ109 and the most interesting potential lead, **27**, in *T. brucei*, to see if similar effects were seen with either or both BSF and procyclic forms (PCF). We first tested whether SQ109 had effects on the proton motive force (more specifically, the inner mitochondrial membrane potential, Δψ) using the safranine method[15,16] with BSF parasites. Figure 4A shows that addition of 10 μM (3.3 μg/mL) SQ109 or 10 μM (4.5 μg/mL) **27** decreased Δψ, which was further reduced by addition of 8 μM (2 μg/mL) FCCP (carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone), a potent protonophore uncoupler. Similar results were obtained with PCF, Figure 4B. *T. brucei* mitochondria were able to phosphorylate ADP, as demonstrated by the small decrease in Δψ after its addition, Figure 4C. This activity was inhibited by the ATP synthase inhibitor oligomycin. In addition, the mitochondria were able to transport Ca^{2+}, as shown by the decrease in the Δψ after addition of $CaCl_2$, and the Δψ returned to basal levels after addition of the Ca^{2+}-chelator EGTA. Further addition of SQ109 or **27** followed by FCCP again collapsed the Δψ, Figure 4C. Both SQ109 and **27** collapsed Δψ in a dose-dependent manner (Figure S3) and SQ109 alone or solvent (0.2 % DMSO) had no effect. These results show that mitochondria in permeabilized *T. brucei* are able to develop a Δψ, phosphorylate ATP and transport Ca^{2+} and that SQ109 and **27** collapse Δψ. These effects on the proton motive force are rapid and are very similar to those observed for SQ109 in bacterial systems[17,18] and are likely to make a significant contribution to SQ109 and **27** inhibiting cell growth.

In addition to their effects on Δψ, it seemed possible that some compounds might act by inhibiting quinone biosynthesis, in some systems, just as other SQ109 analogs did with the prenyl transferase MenA (1,4-dihydroxy-2-naphthoate octaprenyltransferase). We tested a representative set of compounds from the alkanolamine (**5**), imidazolium (**22**, **27**), imidazole

(**39**) and carborane groups (**48**) against an expresssed *E. coli* MenA using the method reported previously[12]. Compounds **22** and **48** had no activity (IC_{50}>40 μM, 20 μg/mL), the IC_{50} for **27** was 19 μM (8.5 μg/mL), for **5**, 9.0 μM (3.6 μg/mL), while that for **39** was 1.5 μM (0.54 μg/mL), suggesting that MenA inhibition with **39** could be of importance in MtE cell growth inhibition (MIC = 3.1 μg/mL). However, **39** has a poor SI.

Overall, the results reported above are of interest since we synthesized a broad range of analogs of the *M. tuberculosis* growth inhibitor, the ethylene diamine SQ109, and tested their activity against bacteria, a fungus, as well as a protozoan parasite. Protonatable or cationic species had the most activity and the most potent leads against *M. tuberculosis* (MIC~0.4–0.5 μg/mL) contained ethanolamine, mercaptoethylamine or imidazolium linkers. The carboranes were less active against *M. tuberculosis* but surprisingly, had activity (IC_{50}~2 μg/mL) against the Gram negative, *E. coli*. However, we did not obtain compounds that were more active against *M. tuberculosis* than was the ethanolamine analog of SQ109 reported earlier. However, we did discover that the parent compound SQ109 had activity against the trypanosomatid parasite, *T. brucei*, the causative agent of human African trypanosomiasis, and that two SQ109 analogs had IC_{50} values in the ~5–7 ng/mL range against this organism with SI values of ~300.

METHODS

Chemical Syntheses: General Methods

All chemicals were reagent grade. ^{1}H NMR and ^{13}C NMR spectra were obtained on Varian (Palo Alto, CA) Unity spectrometers at 400 and 500 MHz for ^{1}H and at 100 and 125 MHz for ^{13}C. Elemental analyses were carried out in the University of Illinois Microanalysis Laboratory. HPLC/MS analyses were performed by using an Agilent LC/MSD Trap XCT Plus system (Agilent Technologies, Santa Clara, CA) with an 1100 series HPLC system including a degasser, an autosampler, a binary pump, and a multiple wavelength detector. All final compounds were ≥90% pure as determined by quantitative spin count NMR (qNMR) and structures were characterized by ^{1}H NMR and HRMS. The synthesis and characterization of all new compounds (**3**-**50**) are shown in the Supporting Information.

T. brucei 427 (bloodstream forms) growth inhibition assay

T. brucei strain 427 bloodstream forms were cultivated at 37 °C with 5% CO_2 in HMI-9 medium supplemented with 10% fetal bovine serum (FBS). *T. brucei* parasites (5×10^4/mL) were seeded in 384 well plates with or without a serial compound dilution. After 72 h of incubation, the parasites were exposed to 120 μM of resazurin sodium salt (Sigma, St. Louis, MO, USA) and were incubated for another 5 h. Then, the parasites were fixed with 4% paraformaldehyde (PFA) and the assay plates were read by using a Victor 3™ fluorimeter (PerkinElmer, Waltham, MA, USA) at an excitation wavelength of 530 nm and emission of 590 nm. Pentamidine was used as a reference drug and DMSO 0.5% was used as a drug-negative control. Two independent sets of experiments were carried out and the mean and standard deviations are shown in Table 1; the R^2 for the pIC_{50} correlation was 0.99.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by NIH grants GM065307, AI049151 and AI104120; a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (NO. 2007-00559), Gyeonggi-do and KISTI.

References

1. Centers for Disease Control and Prevention. [accessed Dec 15, 2014] Threat Report 2013: Antibiotic/Antimicrobial Resistance. http://www.cdc.gov/drugresistance/threat-report-2013/
2. World Health Organization. [accessed Dec 15, 2014] Antimicrobial Resistance: Global Report on Surveillance. 2014. http://www.who.int/drugresistance/documents/surveillancereport/en/
3. World Health Organization. [accessed Dec 15, 2014] Global Tuberculosis Report. 2014. http://www.who.int/tb/publications/global_report/en/
4. Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J, Einck L, Nacy CA. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother. 2005; 56(5):968–974. [PubMed: 16172107]
5. Bogatcheva E, Hanrahan C, Nikonenko B, de los Santos G, Reddy V, Chen P, Barbosa F, Einck L, Nacy C, Protopopova M. Identification of SQ609 as a lead compound from a library of dipiperidines. Bioorg Med Chem Lett. 2011; 21(18):5353–5357. [PubMed: 21807506]
6. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker JR, Alland D, Barry CE, Boshoff HI. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of*Mycobacterium tuberculosis*. Antimicrob Agents Chemother. 2012; 56(4):1797–1809. [PubMed: 22252828]
7. Varela C, Rittmann D, Singh A, Krumbach K, Bhatt K, Eggeling L, Besra GS, Bhatt A. MmpL genes are associated with mycolic acid metabolism in Mycobacteria and Corynebacteria. Chem Biol. 2012; 19(4):498–506. [PubMed: 22520756]
8. Owens CP, Chim N, Goulding CW. Insights on how the *Mycobacterium tuberculosis* heme uptake pathway can be used as a drug target. Future Med Chem. 2013; 5(12):1391–1403. [PubMed: 23919550]
9. Owens CP, Chim N, Graves AB, Harmston CA, Iniguez A, Contreras‡ A, Liptak MD, Goulding CW. The *Mycobacterium tuberculosis* secreted protein Rv0203 transfers heme to membrane proteins MmpL3 and MmpL11. J Biol Chem. 2013; 288(30):21714–21728. [PubMed: 23760277]
10. Makobongo MO, Einck L, Peek RM, Merrell DS. *In vitro* characterization of the anti-bacterial activity of SQ109 against *Helicobacter pylori*. PLoS One. 2013; 8(7):e68917. [PubMed: 23935905]
11. Barbosa, et al. *In vitro* antifungal susceptibility testing of drug candidate SQ109 *Candida albicans*. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Francisco, CA. 2006.
12. Li K, Schurig-Briccio LA, Feng X, Upadhyay A, Pujari V, Lechartier B, Fontes FL, Yang H, Rao G, Zhu W, Gulati A, No JH, Cintra G, Bogue S, Liu YL, Molohon K, Orlean P, Mitchell DA, Freitas-Junior L, Ren F, Sun H, Jiang T, Li Y, Guo RT, Cole ST, Gennis RB, Crick DC, Oldfield E. Multitarget drug discovery for tuberculosis and other infectious diseases. J Med Chem. 2014; 57(7):3126–3139. [PubMed: 24568559]
13. Brynda J, Mader P, Šícha V, Fábry M, Poncová K, Bakardiev M, Grüner B, Cígler P, Řezáčová P. Carborane-based carbonic anhydrase inhibitors. Angew Chem Int Ed. 2013; 52(51):13760–13763.
14. Li W, Upadhyay A, Fontes FL, North EJ, Wang Y, Crans DC, Grzegorzewicz AE, Jones V, Franzblau SG, Lee RE, Crick DC, Jackson M. Novel insights into the mechanism of inhibition of *MmpL3*, a target of multiple pharmacophores in *Mycobacterium tuberculosis*. Antimicrob Agents Chemother. 2014; 58(11):6413–6423. [PubMed: 25136022]

15. Vercesi AE, Bernardes CF, Hoffmann ME, Gadelha FR, Docampo R. Digitonin permeabilization does not affect mitochondrial function and allows the determination of the mitochondrial membrane potential of *Trypanosoma cruzi in situ*. J Biol Chem. 1991; 266(22):14431–14434. [PubMed: 1860850]

16. Huang G, Vercesi AE, Docampo R. Essential regulation of cell bioenergetics in *Trypanosoma brucei* by the mitochondrial calcium uniporter. Nat Commun. 2013; 4:2865. [PubMed: 24305511]

17. Haagsma AC, Podasca I, Koul A, Andries K, Guillemont J, Lill H, Bald D. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PLoS One. 2011; 6(8):e23575. [PubMed: 21858172]

18. Boshoff HI, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE. 3rd, The transcriptional responses of *Mycobacterium tuberculosis* to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem. 2004; 279(38):40174–40184. [PubMed: 15247240]



Figure 1.

Alkanolamine and mercaptoethylamine analogs of SQ109 and their activities against *Mycobacterium tuberculosis* and *Trypanosoma brucei*. Mt = *M. tuberculosis* H37Rv; MtE = *M. tuberculosis* Erdman; Tb = *Trypanosoma brucei*. Values shown are in μg/mL and are MIC for the mycobacteria, and IC_{50} for *T. brucei*.



Figure 2.

Heterocyclic analogs of SQ109 and their activities against *Mycobacterium tuberculosis* and *Trypanosoma brucei*. Mt = *M. tuberculosis* H37Rv; MtE = *M. tuberculosis* Erdman; Tb = *Trypanosoma brucei*; Values shown here are in μg/mL and are MIC for the mycobacteria and IC_{50} for *T. brucei*.



Figure 3.

Carborane-containing analogs of SQ109 and their activities against *Mycobacterium tuberculosis* and *Trypanosoma brucei*. Mt = *M. tuberculosis* H37Rv; MtE = *M. tuberculosis* Erdman; Tb = *Trypanosoma brucei*; Values shown here are in μg/mL and are MIC for the mycobacteria and IC_{50} for *T. brucei*.



Figure 4.

Effects of SQ109 or **27** on Δψ in digitonin-permeabilized *T. brucei*. (A) BSF trypanosomes (2×10^8 cells) were added to reaction buffer (125 mM sucrose, 65 mM KCl, 10 mM Hepes-KOH buffer, pH 7.2, 1 mM $MgCl_2$, 2.5 mM potassium phosphate; 2 mL) containing 20 μM EGTA, 1 mM ATP, 500 μM orthovanadate and 5 μM safranine, and the reaction started with 40 μM digitonin. (B, C) *T. brucei* PCF (5×10^7 cells) were added to the reaction buffer (2.4 mL) containing 2 mM succinate and 5 μM safranine, and the reaction initiated with or without (*yellow* trace in B) 50 μM digitonin. SQ109 (3.3 μg/mL), and **27** (4.5 μg/mL) (equimolar amounts), FCCP (8 μM), ADP (10 μM), oligomycin (Oligo, 2 μg/ml), $CaCl_2$ (12

μM), EGTA (200 μM) were added where indicated. No changes were detected in the absence of digitonin indicating lack of secondary effects of the drugs

Table 1

Growth inhibition of various cells by SQ109 and its analogs.

	Tb[a]	Mt[b]	MtE[c]	Ms[d]	Bs[e]	Ec[f]	Sc[g]	HEK 293T[h]	HepG2[i]	SI(HEK 293T/Tb)[j]	SI(HepG 2/Tb)[k]
1	ND	2.0	ND	1.0	ND	ND	ND	ND	ND	ND	ND
2	0.078±0.001	0.15	0.50	3.1	7.6	2.8	1.1	1.9	1.2	24	15
3	1.5±0.1	3.1	4.0	ND	>120	9.0	25	9.2	4.8	6.0	3.1
4	1.1±0.1	25	16	ND	>120	9.6	2.1	8.8	4.5	7.7	3.9
5	0.75±0.1	0.39	1.0	ND	0.8	0.6	0.7	11	9.4	15	13
6	0.50±0.1	3.1	16	ND	3.0	10	2.8	1.7	1.6	3.4	3.2
7	0.59±0.05	0.78	12	ND	2.1	12	3.2	4.6	2.9	7.8	4.9
8	0.33±0.06	ND	0.78	5.8	2.2	6.2	4.1	6.1	5.4	19	16
9	0.49±0.09	ND	0.78	5.7	3.3	8.0	4.1	9.5	5.6	20	12
10	0.23±0.03	ND	25	5.1	2.8	8.9	5.1	5.2	4.7	23	21
11	0.55±0.1	ND	38	5.2	3.9	9.2	6.1	5.5	3.6	10	6.6
12	7.7±1.5	50	100	ND	>60	>60	>60	18	12.0	2.3	1.6
13	8.1±0.1	50	ND	ND	>60	>60	>60	16	7.3	2.0	0.9
14	4.6±0.4	50	ND	ND	>60	>60	>60	16	12	3.5	2.6
15	3.3±0.5	25	ND	ND	>60	>60	>60	21	20	6.4	6.1
16	0.31±0.02	0.39	16	1.2	1.4	1.4	0.38	2.7	1.6	8.6	5.1
17	0.69±0.12	3.1	8.0	1.1	0.5	0.7	0.1	4.9	4.1	7.1	6.0
18	0.89±0.01	6.2	2.0	4.8	2.3	2.3	2.2	4.7	3.4	5.3	3.8
19	3.4±0.8	12	25	4.6	28	>74	>74	17	19	5.0	5.6
20	2.8±0.1	6.2	ND	5.6	>90	>90	>90	12	12	4.2	4.2
21	0.39±0.01	1.6	6.2	1.2	0.38	2.0	1.5	1.7	1.5	4.4	3.8
22	0.047±0.007	3.1	12	1.5	1.2	36	9.1	3.2	4.3	68	91
23	0.023±0.005	3.1	1.6	0.7	2.1	33	17	4.1	5.4	180	240
24	0.21±0.02	0.78	0.50	3.2	3.1	13	8.4	4.9	6.2	24	30
25	0.058±0.011	ND	3.1	1.2	2.1	12	5.7	2.6	3.1	45	53
26	0.31±0.05	ND	6.2	1.5	2.0	12	4.8	5.1	5.5	17	18
27	0.0055±0.0001	ND	3.1	0.9	0.88	7.2	4.4	1.6	2.0	290	370
28	0.0076±0.0004	ND	6.2	0.9	0.41	5.4	2.2	1.3	1.5	170	200

	Tb[a]	Mt[b]	MtE[c]	Ms[d]	Bs[e]	Ec[f]	Sc[g]	HEK 293T[h]	HepG2[i]	SI(HEK 293T/Tb)[j]	SI(HepG 2/Tb)[k]
29	0.12±0.01	ND	6.2	1.6	0.78	5.6	3.8	3.7	3.7	30	30
30	0.019±0.001	ND	4.6	1.0	0.48	3.4	2.7	1.6	1.9	86	100
31	0.017±0.001	ND	6.2	1.0	0.37	2.0	1.6	1.6	1.5	92	86
32	0.12±0.02	ND	9.3	3.5	0.56	3.6	0.51	4.4	4.2	38	36
33	0.016±0.001	ND	4.6	0.8	0.59	6.7	1.9	1.8	2.1	110	130
34	0.15±0.02	ND	3.1	1.8	0.69	4.0	2.1	3.2	3.5	21	23
35	0.022±0.001	ND	12	2.3	3.3	35	12	3.2	5.4	97	160
36	0.021±0.004	ND	6.2	0.8	0.22	1.0	1.4	1.5	1.5	70	70
37	0.026±0.002	ND	12	0.5	0.24	1.0	1.8	1.9	1.6	73	61
38	3.0±0.5	ND	17	16	1.2	85	46	19	ND	6.3	ND
39	1.4±0.1	ND	3.1	1.1	0.36	4.6	4.5	5.2	6.3	3.8	4.7
40	0.93±0.10	ND	6.2	1.9	1.1	6.4	3.5	3.6	3.4	3.9	3.6
41	0.40±0.06	ND	25	7.3	3.8	19	16	6.3	4.9	16	12
42	0.68±0.07	ND	25	1.3	0.75	2.1	3.4	3.5	3.0	5.1	4.4
43	0.93±0.17	ND	25	3.8	1.6	11	29	7.2	5.1	7.7	5.5
44	0.63±0.09	ND	37	1.9	0.31	5.0	7.3	7.9	7.8	13	12
45	0.49±0.08	ND	25	0.8	0.2	1.8	3.0	4.1	3.7	8.4	7.6
46	0.96±0.09	ND	25	ND	ND	ND	ND	14	14	15	15
47	0.37±0.09	ND	12	ND	ND	ND	ND	2.5	3.1	6.8	8.4
48	0.33±0.05	ND	25	ND	ND	ND	ND	1.9	1.4	5.8	4.3
49	0.61±0.16	ND	100	ND	ND	ND	ND	4.7	4.2	7.6	6.8
50	1.2±0.2	ND	100	ND	ND	ND	ND	7.5	7.9	6.4	6.7
51	0.26±0.07	0.035	ND	1.6	16	2.8	1.8	1.3	1.0	4.9	3.8

[a] Tb = *Trypanosoma brucei*, IC_{50};

[b] Mt = *M. tuberculosis* H37Rv, MIC;

[c] MtE = *M. tuberculosis* Erdman, MIC;

[d] Ms = *M. smegmatis*, IC_{50};

[e] Bs = *B. subtilis*, IC_{50};

[f] Ec = *E. coli*, IC_{50};

[g] Sc = *S. cerevisiae*, IC_{50};

[h] human embryonic kidney, HEK293T, CC_{50};

[i] human hepatocellular carcinoma, HepG2, CC_{50};

[j] SI = CC_{50}(HEK293T)/IC_{50}(Tb);

[k] SI = CC_{50}(HepG2)/IC_{50}(Tb).

All units for MIC, IC_{50} and CC_{50} are μg/mL. The *T. brucei* results show mean and standard deviations of two independent experiments (R^2 for pIC_{50}=0.99); the fitting errors for Ms, Bs, Ec and Sc obtained from dose-response curves (8 half-log dilutions) were 9%, 9%, 11% and 14%, respectively. *M. tuberculosis* inhibition MICs were estimated visually from 2x serial dilutions while human cell growth inhibition was determined from fitting dose-response curves to a rectangular hyperbolic function.